X0206 3 2014-04-09 0 0001328143 Adamas Pharmaceuticals Inc ADMS 0001410787 MDV IX LP C/O MOHR DAVIDOW VENTURES 3000 SAND HILL ROAD, #3-290 MENLO PARK CA 94025 0 0 1 0 0001573991 Ninth MDV Partners, L.L.C. C/O MOHR DAVIDOW VENTURES 3000 SAND HILL ROAD, #3-290 MENLO PARK CA 94025 0 0 1 0 0001027621 FEIBER JONATHAN D C/O MOHR DAVIDOW VENTURES 3000 SAND HILL ROAD, #3-290 MENLO PARK CA 94025 0 0 1 0 0001129541 MDV VII LP C/O MOHR DAVIDOW VENTURES 3000 SAND HILL ROAD, #3-290 MENLO PARK CA 94025 0 0 1 0 0001564546 Seventh MDV Partners, L.L.C. C/O MOHR DAVIDOW VENTURES 3000 SAND HILL ROAD, #3-290 MENLO PARK CA 94025 0 0 1 0 0001250354 SCHOENDORF NANCY J C/O MOHR DAVIDOW VENTURES 3000 SAND HILL ROAD, #3-290 MENLO PARK CA 94025 0 0 1 0 Common Stock 2742702 I MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP Series AA Convertible Preferred Stock Common Stock 1029516 I MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP & MDV ENF VII (B) LP Series AA Convertible Preferred Stock Common Stock 511328 I MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P. Series AA-1 Convertible Preferred Stock Common Stock 468 I MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP & MDV ENF VII (B) LP The shares are held directly by MDV VII, L.P. ("MDV VII"). Jonathan Feiber ("Feiber") and Nancy Schoendorf ("Schoendorf") are managing members of Seventh MDV Partners, L.L.C., the general partner of MDV VII, as nominee for MDV VII, MDV VII Leaders' Fund, L.P., MDV ENF VII(A), L.P, and MDV ENF(B), L.P. Feiber, Schoendorf and MDV VII may be deemed to share voting and investment power over the shares. Feiber, Schoendorf and MDV VII disclaim beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. William Ericson ("Ericson"), a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. The Series AA Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert immediately prior to the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 1 share of Series AA Preferred Stock, for no additional consideration. The shares are held directly by MDV IX, L.P. ("MDV IX"). Ericson and Feiber are Managing Members of Ninth MDV Partners, L.L.C., the general partner of MDV IX, as nominee for MDV IX, and MDV ENF IX, L.P. Feiber, Ericson and MDV IX may be deemed to share voting and dispositive power over the shares held by MDV IX, as nominee for MDV IX, L.P., and MDV ENF IX, L.P. Ericson, Feiber and MDV IX disclaim beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. The Series AA-1 Preferred Stock has no expiration date and will automatically convert immediately prior to the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 1000 shares of Series AA-1 Preferred Stock, for no additional consideration. Except upon the closing of the Issuer's initial public offering, the Series AA-1 Preferred Stock shall not be convertible into Common Stock. MDV VII LP, nominee for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP By: Name: Title: 2014-04-09 MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P. By: Name: Title: 2014-04-09 Seventh MDV Partners, L.L.C. By: Name: Title: 2014-04-09 Ninth MDV Partners, L.L.C. By: Name: Title: 2014-04-09 Jonathan Feiber 2014-04-09 Nancy Schoendorf 2014-04-09